T. Rowe Price Associates’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-67,365
| Closed | -$1.21M | – | 2667 |
|
|
2020
Q2 | $1.21M | Sell |
67,365
-7,351
| -10% | -$102K | ﹤0.01% | 1699 |
|
|
2020
Q1 | $533K | Buy |
74,716
+6,410
| +9% | +$80K | ﹤0.01% | 1960 |
|
|
2019
Q4 | $1.63M | Buy |
68,306
+15,764
| +30% | +$435K | ﹤0.01% | 1682 |
|
|
2019
Q3 | $1.41M | Sell |
52,542
-9,195
| -15% | -$258K | ﹤0.01% | 1673 |
|
|
2019
Q2 | $1.68M | Sell |
61,737
-5,222
| -8% | -$164K | ﹤0.01% | 1651 |
|
|
2019
Q1 | $2.32M | Sell |
66,959
-8,020
| -11% | -$231K | ﹤0.01% | 1542 |
|
|
2018
Q4 | $1.46M | Buy |
74,979
+23,213
| +45% | +$477K | ﹤0.01% | 1656 |
|
|
2018
Q3 | $1.38M | Sell |
51,766
-1,214
| -2% | -$39.6K | ﹤0.01% | 1739 |
|
|
2018
Q2 | $2M | Buy |
52,980
+2,319
| +5% | +$88.7K | ﹤0.01% | 1596 |
|
|
2018
Q1 | $1.66M | Buy |
50,661
+22,311
| +79% | +$979K | ﹤0.01% | 1625 |
|
|
2017
Q4 | $1.38M | Buy |
28,350
+1,400
| +5% | +$70.8K | ﹤0.01% | 1674 |
|
|
2017
Q3 | $1.46M | Buy |
26,950
+3,710
| +16% | +$218K | ﹤0.01% | 1651 |
|
|
2017
Q2 | $1.3M | Hold |
23,240
| – | – | ﹤0.01% | 1680 |
|
|
2017
Q1 | $911K | Sell |
23,240
-90
| -0.4% | -$2.87K | ﹤0.01% | 1823 |
|
|
2016
Q4 | $524K | Sell |
23,330
-10,600
| -31% | -$207K | ﹤0.01% | 2021 |
|
|
2016
Q3 | $771K | Sell |
33,930
-609,289
| -95% | -$14.3M | ﹤0.01% | 1843 |
|
|
2016
Q2 | $15.2M | Buy |
643,219
+5,000
| +0.8% | +$123K | ﹤0.01% | 1185 |
|
|
2016
Q1 | $13M | Buy |
638,219
+359,090
| +129% | +$11.4M | ﹤0.01% | 1208 |
|
|
2015
Q4 | $14.4M | Sell |
279,129
-115,350
| -29% | -$5.59M | ﹤0.01% | 1190 |
|
|
2015
Q3 | $16.8M | Buy |
394,479
+3,700
| +0.9% | +$179K | ﹤0.01% | 1153 |
|
|
2015
Q2 | $17.8M | Sell |
390,779
-18,300
| -4% | -$736K | ﹤0.01% | 1172 |
|
|
2015
Q1 | $15.5M | Sell |
409,079
-20,896
| -5% | -$718K | ﹤0.01% | 1202 |
|
|
2014
Q4 | $12.2M | Sell |
429,975
-87,678
| -17% | -$2.44M | ﹤0.01% | 1267 |
|
|
2014
Q3 | $13.1M | Sell |
517,653
-49,926
| -9% | -$1.31M | ﹤0.01% | 1230 |
|
|
2014
Q2 | $16.6M | Sell |
567,579
-157,956
| -22% | -$3.82M | ﹤0.01% | 1169 |
|
|
2014
Q1 | $18.8M | Buy |
725,535
+92,156
| +15% | +$2.46M | ﹤0.01% | 1126 |
|
|
2013
Q4 | $16.3M | Sell |
633,379
-112,400
| -15% | -$2.73M | ﹤0.01% | 1149 |
|
|
2013
Q3 | $19.7M | Sell |
745,779
-32,000
| -4% | -$761K | ﹤0.01% | 1081 |
|
|
2013
Q2 | $18.9M | Buy |
+777,779
| New | +$15.5M | 0.01% | 1079 |
|
T. Rowe Price Associates's PTLA Position: Q3 2020 in Review
T. Rowe Price Associates sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 67,365 shares — an estimated $1.21M sold.
T. Rowe Price Associates first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $19.7M in Q3 2013. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- T. Rowe Price Associates reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- T. Rowe Price Associates sold 67,365 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.21M.
- T. Rowe Price Associates first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- T. Rowe Price Associates's Portola Pharmaceuticals, Inc. position peaked at $19.7M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on T. Rowe Price Associates's 13F filing for Q3 2020, filed 16 Nov 2020.